Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 127 | 44% |
| 2020 | 1 | 110 | 46% |
| 2021 | 4 | 224 |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arizona; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 23 | 583+5.4%/yr | +5.4%/yr | 0.2 | 32% | 500 in 2030−2.5%/yr |
| Colorado | 9 | 330 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 68 | 2,849+1.1%/yr | +1.1%/yr | 3.71.3× | 2% | 3,400 in 2030+3%/yr |
| Decompression & minimally invasive spine |
SI joint fusion in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
| ≈ 600 |
| – |
| 2026 est. | ≈ 660 | – |
| 49% |
| 2022 | 6 | 316 | 51% |
| 2023 | 3 | 345 | 53% |
| 2024 | 5 | 365 | 54% |
| 2025 from claims | – | 596 482–700 | 55% |
| 2026 forecast | – | 657 514–825 | 55% |
| 2027 forecast | – | 721 535–953 | 56% |
| 2028 forecast | – | 792 561–1,093 | 56% |
| 2029 forecast | – | 870 591–1,247 | 57% |
| 2030 forecast | – | 955 626–1,417 | 57% |
In 2025, 14% inpatient hospital, 18% hospital outpatient, 67% surgery center. The share outside the hospital has moved −11 pts since 2022.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +20%/yr |
| 0.6 |
| 11% |
| 570 in 2030+9.4%/yr |
| Washington | 4 | 187−0.2%/yr | −0.2%/yr | 0.2 | 100% | 80 in 2030−12%/yr |
| Idaho | 2 | 102+43%/yr | +43%/yr | 0.5 | 0% | 170 in 2030+8.4%/yr |
| 72 |
| 2,815−4.4%/yr |
| −4.4%/yr |
| 3.71.2× |
| 14% |
| 3,290 in 2030+2.6%/yr |
| Cervical fusion & disc arthroplasty | 36 | 1,337+2.4%/yr | +2.4%/yr | 1.71.4× | 6% | 1,730 in 2030+4.4%/yr |
| Kyphoplasty & vertebroplasty | 15 | 1,110+2.9%/yr | +2.9%/yr | 1.51.7× | 90% | 1,600 in 2030+6.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
SI-BONE leads with 75% of company spending on these surgeons in 2025, level with 2024.
In 2025, 6 companies reported engagement with Arizona’s surgeons worth $98K in consulting, speaking, meals and travel tied to these products, about $20K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.